| Previous Close | 101.00 |
| Open | 100.65 |
| Volume | 1,370,735 |
| Avg. Volume (3M) | 1,772,758 |
| Market Cap | 8,253,955,584 |
| Price / Earnings (TTM) | 14.30 |
| Price / Earnings (Forward) | 8.34 |
| Price / Sales | 1.06 |
| Price / Book | 0.870 |
| 52 Weeks Range | |
| Earnings Date | 6 Mar 2026 |
| Profit Margin | 9.82% |
| Operating Margin (TTM) | 12.83% |
| Diluted EPS (TTM) | 9.71 |
| Quarterly Revenue Growth (YOY) | -4.80% |
| Quarterly Earnings Growth (YOY) | 24.50% |
| Total Debt/Equity (MRQ) | 37.12% |
| Current Ratio (MRQ) | 1.29 |
| Operating Cash Flow (TTM) | 1.16 B |
| Levered Free Cash Flow (TTM) | 901.28 M |
| Return on Assets (TTM) | 4.35% |
| Return on Equity (TTM) | 8.30% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | ICON plc | Bearish | Bearish |
AIStockmoo Score
0.4
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -4.0 |
| Average | 0.38 |
|
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Mid Value |
| % Held by Insiders | 0.63% |
| % Held by Institutions | 92.70% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 222.00 (Truist Securities, 109.18%) | Hold |
| Median | 120.00 (13.07%) | |
| Low | 120.00 (Citigroup, 13.07%) | Hold |
| 120.00 (Barclays, 13.07%) | Hold | |
| 120.00 (TD Cowen, 13.07%) | Buy | |
| Average | 143.40 (35.12%) | |
| Total | 2 Buy, 3 Hold | |
| Avg. Price @ Call | 120.96 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citigroup | 11 Mar 2026 | 120.00 (13.07%) | Hold | 105.38 |
| Barclays | 09 Mar 2026 | 120.00 (13.07%) | Hold | 110.03 |
| Jefferies | 23 Feb 2026 | 135.00 (27.20%) | Buy | 104.66 |
| TD Cowen | 18 Feb 2026 | 120.00 (13.07%) | Buy | 96.50 |
| 22 Jan 2026 | 183.00 (72.43%) | Hold | 186.74 | |
| Truist Securities | 08 Jan 2026 | 222.00 (109.18%) | Hold | 188.22 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 27 Jan 2026 | Announcement | ICON’s Accellacare Site Network Expands Oncology Research Capabilities With New Cancer Institute Partnership |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |